Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Stock analysts at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research note issued on Thursday, October 17th. Cantor Fitzgerald analyst A. Young anticipates that the company will post earnings per share of ($0.93) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2020 earnings at ($1.28) EPS.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last released its quarterly earnings results on Tuesday, August 6th. The company reported C($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.20) by C($0.03). The company had revenue of C$0.04 million for the quarter, compared to analysts’ expectations of C$0.07 million.
Aurinia Pharmaceuticals stock opened at C$6.19 on Monday. Aurinia Pharmaceuticals has a 12-month low of C$4.70 and a 12-month high of C$10.47. The company has a market capitalization of $499.35 million and a price-to-earnings ratio of -8.88. The company has a debt-to-equity ratio of 0.33, a current ratio of 18.98 and a quick ratio of 18.05. The firm’s fifty day moving average price is C$7.29 and its 200 day moving average price is C$8.10.
In other news, Senior Officer Bradley Dickerson purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were purchased at an average price of C$5.11 per share, with a total value of C$25,542.00. Following the purchase, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately C$76,626. Insiders have purchased a total of 9,550 shares of company stock worth $53,567 in the last ninety days.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Read More: What are catch-up contributions?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.